AstraZeneca PLC

AZNCF

Get informed when a big investor buys or sells

Market Cap$294.4B

Close$

Compare to Similar Companies

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
AstraZeneca PLC	25.3	1.87%	21%	5.1	0.6

Earnings Call Q2 2026

July 27, 2026 - AI Summary

Strong H1 momentum + unchanged full-year guidance - Total revenue +6% in 1H26; +11% excluding Farxiga & Brilinta (generic/Loss-of-Exclusivity headwinds). - Core EPS +11% in 1H, in line with full-year guidance. - Outlook reiterated: full-year total revenue mid- to high single-digit growth and core EPS low double-digit growth at CER (constant exchange rates).

Pipeline delivery remains a key driver (6 Phase III readouts; many catalysts ahead) - 6 positive Phase III program results in 1H26, including first pivotal data for 3 new molecular entities (NMEs) and 3 new molecular entity approvals. - 30 major market approvals in the first half; NME approvals increased to 11 since the 2030 target (goal: 20 NMEs by 2030). - Catalyst path: 25 key Phase III readouts planned over the next 18 months; 6 NME pivotal data readouts expected in 2027 (major opportunity to sustain growth beyond patent losses).

What’s “good”: Oncology strength + new ADC/respiratory momentum - Oncology revenues +15% to $14.1B in H1, with strong regional growth (notably U.S. +18%, Europe +16%). - Notable oncology momentum: - Enhertu +31% in Q2 to $888M; continued leadership in HER2-positive/low breast and encouraging adoption in curative settings (DESTINY programs). - Imfinzi + Imjudo +25% in Q2 (aggregate); rapid adoption in gastric cancer with MATTERHORN and progress in bladder. - Datroway shows accelerating adoption signals; launch/readiness for TROPION-Breast02-related opportunity. - Surprising/major positive science: CLARITY-Gastric01 (sone-ve ADC) showed overall survival benefit in Claudin 18.2+ advanced gastric cancer (2nd-line plus), with OS benefit also potentially expanding to patients with lower C18.2 expression (as low as ~25% staining).

Exclusive for Stockcircle Pro members

$423.09

Current Fair Value

122.8% upside

Undervalued by 122.8% based on the discounted cash flow analysis.

Share Statistics

Market cap	$294.40 Billion
Enterprise Value	$319.39 Billion
Dividend Yield	$2.63 (1.87%)
Earnings per Share	$6.6
Beta	0.19
Outstanding Shares	1,551,000,000

Return

Return on Equity	21.16%
Return on Assets	9.03%
Return on Invested Capital	16.80%

Valuation & Multiples

P/E Ratio	25.34
PEG	46.03
Price to Sales	5.13
Price to Book Ratio	6.13
Enterprise Value to Revenue	5.44
Enterprise Value to EBIT	22.78
Enterprise Value to Net Income	31
Total Debt to Enterprise	0.1
Debt to Equity	0.63

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date

April 29, 2026

EPS Estimate

Average shareholder expectation

Revenue Estimate

$15.44 B

Average shareholder expectation

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

ESG Score

No data

About AstraZeneca Plc

CEO: Pascal Soriot

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...

Relevant Senate Committees

Finance

Most powerful committee for pharma; oversees Medicare and Medicaid. It dictates drug pricing negotiations, rebate policies, and international tax laws that affect corporate earnings.

Appropriations

Determines the actual funding levels for the FDA and NIH, influencing the speed of drug approvals and the amount of federal funding available for collaborative biomedical research.

Health, Education, Labor, and Pensions

Directly oversees the FDA and NIH; this committee's legislation determines the regulatory hurdles for drug approval and clinical trials, which is fundamental to AstraZeneca's pipeline.

Judiciary

Controls intellectual property and patent law; AstraZeneca's valuation is heavily dependent on patent protections and the prevention of generic competition managed through this committee's jurisdiction.

Special Committee on Aging

Investigates drug pricing, Medicare, and conditions like cancer and cardiovascular health, which are core therapeutic areas for AstraZeneca; its hearings create significant headline and reputational risk.

Veterans' Affairs

The Department of Veterans Affairs is one of the largest purchasers of drugs in the world; committee decisions regarding VA formularies and drug pricing directly impact AstraZeneca's US revenue.